An unhealthy combination of factors resulted in an unhealthy day on the stock market for next-generation healthcare company BioNTech (NASDAQ: BNTX). Investors were concerned about the latest top-level ...

The type of vaccine it's most famous for might be cast in a very unflattering light in the very near future.. Citing four unnamed people "familiar with the situation," this effort will be based on ...

People aiming to get its Comirnaty Covid vaccine won't need a doctor's prescription to do so. This was among several measures being considered by an advisory panel to the CDC. 10 stocks we like better ...

BioNTech (BNTX) stock is down nearly 20% at the time of writing after the German company posted a Q4 loss, issued muted guidance, and said its cofounders will depart by the end of this year CEO Uğur ...

Germany-based BioNTech (NASDAQ: BNTX) saw its U.S. listed stock enjoy a mini-pop on Wednesday, and for once this wasn't largely based on the Comirnaty COVID-19 vaccine it developed with Pfizer. Rather ...

BioNTech SE (NASDAQ:BNTX) is one of the best high growth healthcare stocks to buy now. On March 11, BMO Capital cut the price ...

In the latest quarter, 6 analysts provided ratings for BioNTech (NASDAQ:BNTX), showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates ...

We came across a bullish thesis on BioNTech SE on Memyselfandi007’s Substack. In this article, we will summarize the bulls’ thesis on BNTX. BioNTech SE’s share was trading at $103.80 as of March 4th.

BioNTech SE has unveiled compelling clinical results for a key oncology candidate, providing a tangible milestone in its strategic pivot away from its pandemic-era business. The data, presented at a U ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...